{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-068248","form_type":"8-K","ticker":"HOOK","cik":"0001760542","company_name":"HOOKIPA Pharma Inc.","filed_at":"2024-06-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.937531+00:00","generated_at":"2026-06-01T06:34:52.263394+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"HOOKIPA reports 53% ORR in CPS≥20 subgroup from Phase2 HB-200 + pembro trial at ASCO","bullets":["Among 35 evaluable first-line HPV16+ HNSCC patients, ORR 37%, CR 11%, DCR 69% per RECIST 1.1.","In CPS≥20 subgroup (N=17, registrational target): ORR 53%, CR 18%, DCR 82%; PFS 16.3 mo, OS rate 88% at 9 mo.","HB-200 + pembrolizumab well-tolerated; Grade≥3 TRAEs in 15%, no treatment-related deaths.","Company plans to begin pivotal Phase 2/3 trial in Q4 2024 with FDA alignment on path to accelerated approval.","Data presented as oral abstract at ASCO 2024; median follow-up for CPS≥20 subgroup was 8.4 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-068248","json":"https://secwatch.observer/filing/0001104659-24-068248.json","markdown":"https://secwatch.observer/filing/0001104659-24-068248.md","text":"https://secwatch.observer/filing/0001104659-24-068248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1760542/000110465924068248/0001104659-24-068248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1760542/000110465924068248/tm2416401d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:34:52.263394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}